Hunterr, see this article and you will get some indication how to get more than one BP to be very interested in RC220 (assume it is proven as we'd like and expect). There is far too much money for them to lose to generics and they want replacement (they also have shareholders who want return). Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’ | BioPharma Dive
Speculative M&A Transaction Analysis, page-854
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.005(0.34%) |
Mkt cap ! $250.5M | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.50 | $1.46 | $129.2K | 87.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7418 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 38353 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |